Overview
A life science and deeptech fund unlocking the power of novel therapeutics.
ÓSKARE CAPITAL, has launched the first AIFM and ESG compatible Venture Capital fund with an investment focus on innovative companies and teams in Europe working on novel therapeutics that target the endocannabinoid system as well as the ‘picks and shovels’ of the associated ecosystem of services and products that support this fast-growing global market. We are the first fund taking this approach and have a unique pipeline of deals.
Opportunity
With a highly favorable legal and regulatory landscape in Europe, this sector is a high growth market (€15 B in 2029) and will continue to disrupt the wider market of diseases addressable via the endocannabinoid system (€438 B today).
There are promising new endocannabinoid therapeutic solutions under study for epilepsy, pain, spasticity, anxiety, and sleep oncology, cardiovascular conditions, Autism and Down's Syndrome among others.
Óskare Capital has identified a large number of companies in its dealflow pipeline with strong teams, disruptive IP and scalable technologies.
Funds
Óskare Fund 1 | €50 M target | AIFM domiciled in Dublin, Ireland (ICAV) | Spin-out to Series B + | European focus, global remit. Best ESG practices.
Management team based in Paris and London with expertise in VC, pharmacology, oncology and systems engineering.
Scope
Focus on scientific innovation and solutions that offer tangible outcomes in the wellness and medical sectors for which there is strong scientific rationale to leverage the power of the endocannabinoid system.
Investments in science, services and solutions with high barriers to entry and sustained value.
The fund will prioritize opportunities that are protected by strong intellectual property and compelling business propositions.
As Featured In
“Only a subset of investors and entrepreneurs go into these spaces, but the size of the prize is massive”
